Adaptive Phage Therapeutics
Life sciences company developing treatments for drug resistant bacteria.
Based in MD
AI Overview
With $80K in lobbying spend across 22 quarterly filings, Adaptive Phage Therapeutics is an active lobbying client. Their lobbying covers 2 issue areas. Active from 2020 to 2025.
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2020 | $80K |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $0 |
| 2025 | $0 |
Issues Lobbied
Lobbying Firms
Lobbyists
Government Agencies Targeted
These are the government entities that Adaptive Phage Therapeutics disclosed contacting in their lobbying filings.
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues, MED
Promoting federal policies to develop therapeutics to combat drug resistant bacterial infections
Advocacy for federal funding related to the development of phage therapeutics to combat anti-microbial resistance
Related Analysis
Related Investigations
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.